

14. Sophia K, Apple J, Randolph H, et al. Immunohistochemical evaluation of K-ras, P53 and HER-2/neu expression in hyperplastic, dysplastic and carcinomatous lesions of the pancreas: evidence for multistep carcinogenesis. *Human Pathology* 1999; 30(2): 123-130.
15. Grigioni WF, D'errico A, Bacci F, et al: Primary liver neoplasms: evaluation of proliferative index using MoAb Ki-67. *J. Of Pathology* 1989; 158:23-29.
16. Farrugia M, Duan LJ, Reis MD, et al: Alterations of the P53 tumor suppressor gene in diffuse large cell lymphomas with translocations of the C-MYC and Bcl-2 proto-oncogenes. *Blood* 1994; 83:191-198.
17. Vera -Bravo R, Ocampo M, Urquiza M, Garcia JE, Rodriguez LE, Puentes A, Lopez R, et al: Human papillomavirus type 16 and 18 LI protein peptide binding to Vero and Hela cells inhibit their VLP<sub>s</sub> binding. *Int.J.Cancer* 2003; 107:416-424.
18. Amrani M, Lalaoui K, El-Mzibri M, Lazo P, Belabbas MA. Molecular detection of human papillomavirus in 594 uterine cervix samples from Moroccan women (147 biopsies and 447 swabs). *Journal of Clinical Virology* 2003; 27:286-295.
19. Abdulla AM. A study on Human Papillomavirus: High-risk HPV E6, P53 and P16 Proteins expression and their role in cervical carcinogenesis. 2006.
20. Abbas SM. Application of Immunohistochemical and Histochemical Stains in Diagnosis of Cervical Tumors. 2002.
21. Koyamatsu Y, Yokoyama M, Fukuda K, Saito T, Mastsukiima K, Ivvasaka T: A comparative analysis of human papillomavirus type 16 and 18 and expression of p53 gene and Ki-67 in cervical, vaginal and vulvar carcinomas. *Gynecologic Oncology* 2002; 90:547-551.
22. Nair P, Nair MIC, Jayaprakash PG, Pillai MR. Decreased programmed cell death in uterine cervix associated with high risk human papillomavirus infection. *Pathology Oncology Research* 1999; 5(2): 95-103.
23. Cheah PL, Looi L.M. P53 immunohistochemical expression: messages in cervical carcinogenesis. *Pathology* 2002; 34:326-331.
24. Kersemaekers AM, Fleuren GJ, Kenter GG, Van Den Brock LJ, Uljee SM, Hermans J, Van Den Vijver MJ. Oncogene alterations in carcinomas of the uterine cervix: overexpression of the epidermal growth factor receptor is associated with poor prognosis. *Clin. Cancer Res.* 1999; 5(3): 577-586.
25. Kainz C, Kohlberger P, Gitsch G, Sliutz G, Breitenacker G, Reinthaller A: Mutant p53 in patients with invasive cervical cancer stages IB to IB. *Gynecol Oncol* 1995; 57(2): 212-214.
26. Abd EI, All H, and Rye A, Duvillard P: P53 immunohistochemical expression of Egyptian cervical carcinoma. *Pathology Oncology Research* 1999; 5(4): 280-284.
27. McCluggage G, Yoshihama Y, Kimura T, Shintani S, Alcalde RE: P53 and MDM2 expression in oral squamous cell carcinoma. *Oncology* 1996; 53:308-312.
28. Quinn MA: Adenocarcinoma of the cervix- Are there arguments for treatment policy? *Current Opinion in Obst Gynecol* 1997.
29. Negan HY, Tsao SW, Liu SS, Stanley M: Abnormal expression and mutation of P53 in cervical cancer – a study at protein, RNA and DNA levels. *Genitourin. Med.* 1997; 73:54-58.
30. Tenti P, Romagnoli S, Silini E, Zappatore R, Giunta P, and Stella G, Carnevali L: Cervical adenocarcinoma expresses markers common to gastric, intestinal and pancreatobiliary epithelial cells. *Pathol Res Pract* 1998.
31. Zheng A, Castren K, Saily M, et al: P53 status of newly established acute myeloid leukemia cell lines. *Br.J.Cancer* 1999; 79(314): 407-415.
32. Berns EM, Klijn J, Putten W, et al: P53 protein accumulation predicts poor response to Tamoxifen therapy of patients with recurrent breast cancer. *J.Clin.Oncology* 1998; 16:121-127.
33. Villuendas R, Pezzella F, Gatter K, et al: P21 waf 1/cip 1 and MDM2 expression in Non-Hodgkin's lymphoma and their relationship to P53 status: A P53 +, MDM2<sup>-</sup>, P21<sup>-</sup> immunophenotype associated with missense P53 mutations. *J. of Pathol.* 1997; 181:51-61.
34. Andersson S, Hellstrom AC, Ren ZP, Wilander E: The carcinogenic role of oncogenic HPV and P53 gene mutation in cervical adenocarcinomas. *Oncology* 2006; 23(1): 113-119.
35. Wang JL, Zheng BY, Li XD, Angstrom T, Lindstrom MS, Wallin KL. Predictive significance of the p16 INK4A, p14 ARF, p53 and proliferating cell nuclear antigen expression in the progression of cervical cancer. *Clinical Cancer Research* 2004; 10:2407-2414.
36. Vassallo J, Derchain SFM, Pinto GA, Martinez EZ, Syrjanen KJ, Andrade LAL. High risk HPV and p53 protein expression in cervical intraepithelial neoplasia. *International Journal of Gynecology and Obstetrics* 2000; 71:45-48.
37. Du M, Peng H, Singh N, et al. The accumulation of P53 abnormalities is associated with progression of mucosa-